Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells

Biochemical and Biophysical Research Communications

Volumn 399, Issue 4, 2010, Pages 575-580

  Kavitha, C V ^a   Choudhary, Bibha ^a   Raghavan, Sathees C ^a   Muniyappa, K ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Cancer; Etoposide; MRN complex; Telomerase; TRAP assay

Indexed keywords

ETOPOSIDE; MRE11 PROTEIN; NIBRIN; PROTEIN SUBUNIT; RAD50 PROTEIN; SMALL INTERFERING RNA; TELOMERASE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; MRE11A PROTEIN, HUMAN; NBN PROTEIN, HUMAN; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD50 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SOMATIC CELL; DOUBLE STRANDED DNA BREAK; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TELOMERASE;

EID: 77956261995     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.117     Document Type: Article

References (34)

1. Lieber M.R. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem. 2010, 79:181-211.
2. Mimitou E.P., Symington L.S. DNA end resection: many nucleases make light work. DNA Repair (Amst) 2009, 8:983-995.
3. You Z., Bailis J.M. DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol. 2010, 20:402-409.
4. Cesare A.J., Reddel R.R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat. Rev. Genet. 2010, 11:319-330.
5. Bishop J., Lowenthal R., Joshua D., Matthews J., Todd D., Cobcroft R., Whiteside M., Kronenberg H., Ma D., Dodds A. Etoposide in acute non-lymphocytic leukemia. Austr. Leuk. Study Group, Blood 1990, 75:27-32.
6. Lodge A., Hall A., Reid M., McIntosh G., Steward M., Anderson J., Horne C., Angus B. Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome. J. Clin. Pathol. 2001, 54:31-36.
7. Bakshi R.P., Galande S., Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit. Rev. Biochem. Mol. Biol. 2001, 36:1-37.
8. Kavitha C.V., Nambiar M., Ananda Kumar C.S., Choudhary B., Muniyappa K., Rangappa K.S., Raghavan S.C. Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. Biochem. Pharmacol. 2009, 77:348-363.
9. Bogliolo M., lyakhovich A., Callen E., Castella M., Cappelli E., Ramirez M.J., Creus A., Marcos R., Kalb R., Neveling K., Schindler D., Surralles J. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J. 2007, 26:1340-1351.
10. Takemura H., Rao V.A., Sordet O., Furuta T., Miao Z.-H., Meng L.H., Zhang H., Pommier Y. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J. Biol. Chem. 2006, 281:30814-30823.
11. Jiang W.Q., Zhong Z.H., Henson J.D., Reddel R.R. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 2007, 26:4635-4647.
12. Hematulin A., Sagan D., Eckardt-Schupp F., Moertl S. NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade. Cell. Signal. 2008, 20:2276-2285.
13. Zhong Z.H., Jiang W.Q., Cesare A.J., Neumann A.A., Wadhwa R., Reddel R.R. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem. 2007, 282:29314-29322.
14. Wurthwein G., Krumpelmann S., Tillmann B., Real E., Schulze-Westhoff P., Jurgens H., Boos J. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide. Anticancer Drugs 1999, 10:807-814.
15. Moriarty T.J., Dupuis S., Autexier C. Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide. Leukemia 2002, 16:1112-1120.
16. Sato N., Mizumoto K., Kusumoto M., Nishio S., Maehara N., Urashima T., Ogawa T., Tanaka M. Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br. J. Cancer 2000, 82:1819-1826.
17. Ward R.J., Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 2005, 68:779-786.
18. Malerba I., Gribaldo L., Diodovich C., Carloni M., Meschini R., Bowe G., Collotta A. Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs. Toxicol. In Vitro 2005, 19:523-532.
19. Akiyama M., Horiguchi-Yamada J., Saito S., Hoshi Y., Yamada O., Mizoguchi H., Yamada H. Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur. J. Cancer 1999, 35:309-315.
20. Lin Z., Lim S., Viani M.A., Sapp M., Lim M.S. Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am. J. Pathol. 2001, 159:711-719.
21. Kironmai K.M., Muniyappa K. Alteration of telomeric sequences and cell senescence caused by mutations in RAD50 of Saccharomyces cerevisiae. Genes Cells 1997, 2:443-455.
22. Boulton S.J., Jackson S.P. Components of the ku-dependent nonhomologous end-joining pathway are involved in telomeric length maintenance and telomeric silencing. EMBO J. 1998, 17:1819-1828.
23. Nugent C.I., Bosco G., Ross L.O., Evans S.K., Salinger A.P., Moore J.K., Haber J.E., Lundblad V. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr. Biol. 1998, 8:657-660.
24. Jiang W.Q., Zhong Z.H., Henson J.D., Neumann A.A., Chang A.C., Reddel R.R. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol. Cell. Biol. 2005, 25:2708-2721.
25. Abuzeid W.M., Jiang X., Shi G., Wang H., Paulson D., Araki K., Jungreis D., Carney J., O'Malley B.W., Li D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J. Clin. Invest. 2009, 119:1974-1985.
26. Burger A.M., Double J.A., Newell D.R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer 1997, 33:638-644.
27. N. Kuranaga, N. Shinomiya, H. Mochizuki, Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study, BMC Cancer 1 (2001).
28. Wang X., Wong S., Pan J., Tsao S., Fung K., Kwong D., Sham J., Nicholls J. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998, 58:5019-5022.
29. Jeyapalan J., Leake A., Ahmed S., Saretzki G., Tilby M., Von Zglinicki T. The role of telomeres in etoposide induced tumor cell death. Cell Cycle 2004, 3:1169-1176.
30. Klapper W., Qian W., Schulte C., Parwaresch R. DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia 2003, 17:2007-2015.
31. Ku W.C., Cheng A.J., Wang T.C. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. 1997, 241:730-736.
32. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 2003, 131:254-263.
33. Jurianz K., Ziegler S., Donin N., et al. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int. J. Cancer 2001, 93:848-854.
34. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin. Cancer Res. 2009, 15:6314-6320.